Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.

Abstract: Aromatic compounds having a perfluoroalkyl group and a gelling agent for gelling an organic liquid which is composed of any one of them. This gelling agent can gel many kinds of organic liquids by adding a small amount thereof.

Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.

Abstract: A compound represented by the following formula (1) is provided as a gelling agent for gelatinizing a liquid organic compound: wherein n and m are each independently an integer of 2 to 18, R1 and R3 are each independently a single bond or a branched or linear alkylene group having 1 to 6 carbon atoms, R2 is a branched or linear alkylene group having 3 to 18 carbon atoms, and Z1 and Z2 are each independently a phenylene group or a biphenylene group.

Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.

Abstract: To provide a gelling agent containing a fluoroalkyl derivative, a small amount of which can gelatinize or solidify various organic solvents. The gelling agent for organic liquids contains a fluoroalkyl derivative represented by the following formula: wherein each of m, n and x is a positive integer.

Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.

Abstract: Each of unit cells constituting a negative permeability medium includes a metal patch formed on a surface of a dielectric substrate. The dielectric substrate has a rear surface having a ground conductor formed on its entire surface. A positive permeability medium is an existing micro strip line and each of unit cells has a two-dimensional structure having a metal strip connected in four directions. The dielectric substrate has a rear surface having a ground conductor formed on its entire surface. The negative permeability medium is arranged at the left side adjacent to the positive permeability medium formed by unit cells arranged at the right side so that the media oppose to each other. A waveguide formed by the positive/negative permittivity medium or the positive/negative permeability medium of the meta material for propagation of a surface wave is formed at the boundary of the two media.

Abstract: A two-dimensional structure medium comprising a conductor pattern as unit cells formed on the upper surface of a substrate and a conductor pattern formed on the lower surface of the substrate and exhibiting a left-handed characteristic achieved without using a via by utilizing the interaction between an inductance component formed by connecting a part of a floating island pattern out of the conductor pattern on the lower surface of the substrate with a pattern as the ground portion and a capacitance component of parallel-plate mode formed by the conductor pattern on the upper surface of the substrate and the conductor pattern on the lower surface of the substrate.

Abstract: It is intended to provide a method capable of introducing an arbitrary modification group into a synthetic protein and a method capable of easily controlling the syntheses of a modified protein and an unmodified protein. The present invention provides a method of cell-free protein synthesis comprising: performing cell-free protein synthesis using as a reaction solution of cell-free protein synthesis, a mixture solution of an extract derived from a eukaryotic cell and a reagent solution comprising as a substrate, a substance having a desired group to be introduced as a post-translational modification group; and thereby obtaining a protein comprising the post-translational modification group introduced therein. Preferably, the group to be introduced is an acyl group of fatty acid, and the form of the post-translational modification is lipid modification at the N-terminus of the protein.